Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Osteoporosis 5 Prostatic Neoplasms 3 Breast Neoplasms 3 Hypogonadism 2 Uterine Cervical Neoplasms 1 Ovarian Neoplasms 1 Neoplasms 1 Neoplasm Metastasis 1 Genetic Diseases, Inborn 1 Esophageal Neoplasms 1 Carcinoma, Squamous Cell 1 Adenocarcinoma 1

Interventions

Paclitaxel 328 Carboplatin 323 Bevacizumab 171 Gemcitabine 106 liposomal doxorubicin 104 pembrolizumab 101 Cyclophosphamide 96 Topotecan 94 olaparib 92 Cisplatin 92 niraparib 69 Docetaxel 57 Taxes 52 Doxorubicin 51 Drug Therapy 45 fludarabine 40 Filgrastim 39 Nivolumab 37 Magnetic Resonance Spectroscopy 34 Surveys and Questionnaires 33 Specimen Handling 33 Etoposide 32 Hyperthermic Intraperitoneal Chemotherapy 31 Blood Specimen Collection 29 Immunoglobulin G 27 Disulfides 27 Peripheral Blood Stem Cell Transplantation 26 Cytoreduction Surgical Procedures 25 Albumin-Bound Paclitaxel 25 durvalumab 24

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Ovarian Neoplasms × Alendronate × Clear all

NCT00593580 2011-06-29

FOSAVANCE

British Columbia Cancer Agency

Phase 2 Completed

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡